Daniel Petroni
Allergy & Immunology · Seattle, WANPI 1073808028
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 22.2%. Reporting peaked in 2023 at $29,559 and has fallen 75.8% since, to $7,165 in 2024. Among allergy & immunology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 250 payments — averaging $271.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Blueprint Medicines Corporation$15K
- Takeda Pharmaceuticals U.S.A., Inc.$12K
- Aimmune Therapeutics, Inc.$11K
- Biocryst US Sales Co., LLC$6K
- AstraZeneca$6K
- Genentech, Inc.$6K
- plus $12K from 21 others
Across 516 payments — averaging $3828.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$915K
- Aimmune Therapeutics, Inc.$433K
- Novartis$263K
- AstraZeneca$159K
- Takeda Pharmaceuticals U.S.A., Inc.$86K
- Biocryst Pharmaceuticals, Inc.$69K
- plus $51K from 4 others
What the payments were for
- Consulting fees$27,81741%
- Speaking & faculty fees$26,30139%
- Travel & lodging$5,4008%
- Food & beverage$8,39312%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Blueprint Medicines Corporation | 22 | $15,046 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $11,798 |
| Aimmune Therapeutics, Inc. | 14 | $11,362 |
| Biocryst US Sales Co., LLC | 7 | $5,965 |
| AstraZeneca | 62 | $5,895 |
| Genentech, Inc. | 7 | $5,683 |
| Jubilant Hollisterstier LLC | 2 | $4,000 |
| Sanofi | 21 | $2,821 |
| Astrazeneca UK Limited | 12 | $1,628 |
| Biocryst Pharmaceuticals, Inc. | 2 | $1,091 |
| AbbVie | 4 | $995 |
| Alk-abello, Inc | 3 | $341 |
| Pfizer | 20 | $287 |
| Genentech USA, Inc. | 2 | $158 |
| Boehringer Ingelheim | 3 | $144 |
| GSK | 7 | $136 |
| Amgen | 5 | $116 |
| Kaleo, Inc. | 5 | $103 |
| Regeneron | 2 | $77 |
| ADMA Biomanufacturing LLC | 2 | $54 |
| Sanofi Pasteur Inc. | 1 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Novartis | 2 | $27 |
| CSL Behring | 1 | $27 |
| Optinose US, Inc. | 1 | $25 |
| Merck | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$67,911 in reported general payments places this provider in the 95th percentile of 81 allergy & immunology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 14 | $38,427 |
| Spiriva RespimatTiotropium Bromide | 12 | $9,081 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $4,808 |
| Montelukast Sodium | 35 | $1,654 |
| Azelastine Hcl | 18 | $828 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $375 |
| Famotidine | 12 | $174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $5,683 | $38,42714 claims |
| Boehringer IngelheimSpiriva Respimat | $144 | $9,08112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 81 allergy & immunology providers in Washington.
Other allergy & immunology in Seattle
- Frank VirantSeattle$107K
- Leonard AltmanSeattle$81K
- Rahool DaveSeattle$42K
- Matthew AltmanSeattle$37K
- Gabriel MendozaSeattle$16K
- Kelly ColasSeattle$14K
- Jing Yi SunSeattle$11K
- Paul WilliamsSeattle$7K
- Susan XieSeattle$7K
- Matthew PerezSeattle$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.